Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20543Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Bourantas, K. L. | en |
| dc.contributor.author | Tsiara, S. | en |
| dc.contributor.author | Christou, L. | en |
| dc.date.accessioned | 2015-11-24T19:08:33Z | - |
| dc.date.available | 2015-11-24T19:08:33Z | - |
| dc.identifier.issn | 0902-4441 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20543 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Anemia, Refractory/drug therapy/mortality | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Isotretinoin/adverse effects/*therapeutic use | en |
| dc.subject | Leukemia, Myelomonocytic, Chronic/drug therapy/mortality | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Myelodysplastic Syndromes/*drug therapy/mortality | en |
| dc.subject | Survival Rate | en |
| dc.subject | Time Factors | en |
| dc.subject | Vitamin E/therapeutic use | en |
| dc.title | Treatment of 34 patients with myelodysplastic syndromes with 13-CIS retinoic acid | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/7589340 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1600-0609.1995.tb00263.x/asset/j.1600-0609.1995.tb00263.x.pdf?v=1&t=h0p0xunh&s=9603146785bf35a080e7815fd4fa7a2cad4c9abe | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1995 | - |
| heal.abstract | Thirty-four patients with myelodysplastic syndromes, 23 men and 11 women, aged between 47 and 80 years, with all types of myelodysplastic syndromes were treated with 13-cis-retinoic acid. The dose of retinoic acid ranged between 10 and 60 mg/m2/daily and was administered in combination with vitamin E to diminish side effects. The duration of treatment was 3 months to 5 years. Partial remission was achieved in 4 patients, 1 with RA type, 2 with RAEB and 1 with CMML. Survival ranged from 1 to 5 years. Patients who received retinoic acid developed mild side effects. In conclusion, the administration of 13-cis-retinoic acid improves the hematological picture in a small number of MDS patients (11.7%). | en |
| heal.journalName | Eur J Haematol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Bourantas-1995-Treatment of 34 pati.pdf | 420.24 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
